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Abstract
Purpose. Extraskeletal osteosarcoma represents an unusual soft-tissue sarcoma that historically is reported to carry an
exceptionally poor prognosis.The objectives of this study were to use a prospectively gathered sarcoma database to test the
prevailing clinical bias and more accurately describe the natural history, characterize the prognostic features, estimate
survival and evaluate treatment strategies for this unusual sarcoma.
Patients and methods. From a large database of nearly 4000 sarcomas at a single institution, 15 patients with pathologically
con® rmed extraskeletal osteosarcoma were analysed.
Results and discussion. Extraskeletal osteosarcoma usually occurs as a large, deep, high-grade lesion in the lower extremity
of older patients. Overall and disease-speci® c survival at 5 years was 50%, with a median follow-up of 35 months (range
3± 200 months). Use of adjuvant chemotherapy or radiation therapy did not appear to in¯ uence survival, but an effect may
have been missed by the relatively low numbers in each group.When matched to a comparable group of patients with stage
III extremity sarcomas, there was no signi® cant difference in overall or disease-speci® c survival between groups.Treatment
for extraskeletal osteosarcoma should follow established guidelines for treatment of soft-tissue sarcomas, with the decision
regarding adjuvant therapy to be based on individual risk factors.
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Introduction
Extraskeletal osteosarcoma (ESOS) is a malignant
mesenchymal neoplasm capable of osteoid, bone or
chondroid matrix production, located in the soft
tissues and without connection to the skeleton, as
determined by radiographic and intra-operative
examination.
1 As compared with osteosarcoma of
bone,ESOS is rare and occurs infrequentlyin patients
under 40 years of age. Although several studies have
associated the diagnosis of ESOS with a poor
prognosis with an estimated mortality between 70%
and 80%, only limited clinical information exists
regarding the natural history of this unusual
sarcoma.
1± 4 Most series reported to date represent
retrospective reviews, spanning up to 73 years in
length, with the largest series containing 88 patients
and often lackingpathologic con® rmation or adequate
follow-up information.
5,6Previousprospectivestudies
of soft-tissue sarcomas have not analyzed extraskel-
etal osteosarcomas separately, as the number of cases
remains small.
7
The objective of this study was to analyze a cohort
of patients, testing the prevailing clinical bias that
ESOS behaves in a highly aggressive fashion.In addi-
tion,we soughtmoreaccuratelyto describethe natural
history, characterize the prognosticfeatures, estimate
survival and evaluate treatment strategies for this
unusual soft-tissue sarcoma.
Patients and methods
From 1 July 1982 to 30 June 1999, 3969 patients
over the age of 16 years with soft-tissue sarcomas
were admitted for treatment to the Memorial Sloan±
Kettering Cancer Center and followed prospectively.
Of these patients, 15 had pathologically con® rmed
ESOS and form the basis of this review.
For the purposes of this study, ESOS was de® ned
as a sarcoma of the soft tissues having no attachment
to bone or periosteum and which has a histologic
appearance indistinguishable from that of primary
osteogenic sarcoma of bone. Microscopically, the
diagnostic features include the presence of matrix
production,such as neoplastic osteoid or bone,and a
not infrequent association with malignant cartilage.
As with skeletal osteogenic sarcoma, the tumor cells
of ESOS resemble either ® brosarcoma, malignant
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malignant osteoblasts (osteoblastic osteosarcoma) or
chondroblasts (chondroblastic osteosarcoma). Cases
with minimal neoplastic osteoid formation,
indistinguishable from malignant ® brous histiocy-
toma with malignant osseous metaplasia, were
excludedfrom the analysis.
8Patients who had a prior
history of osteogenic sarcoma of the bone were also
excluded. ESOSs of visceral organs (such as breast,
uterus,bladder and kidney) were not included in the
study, as in many of these tumors the presence of an
epithelial component, suggesting carcinosarcoma,
could not be ruled out. Furthermore, dedifferenti-
ated tumors, such as liposarcoma, with osteogenic
features were not included. Some patients had
pre-operative imaging (plain ® lms, computed tomog-
raphy (CT) scan or magnetic resonance imaging
(MRI) that showed no bony attachments; however,
the ® nal determination ruling out bone involvement
was based on operative and pathology reports.
Data analyzed includedpatient characteristics (age,
gender), tumor characteristics (size, grade, depth,
location, histologic subtypes, local and distant recur-
rence), treatment (operation, microscopic margins,
chemotherapy, radiation therapy) and clinical status
as of 30 June 1999.
Since the majority of the ESOSs identi® ed in the
database were high-grade, deep and large lesions of
the extremity (i.e. stage III), a comparison group of
all extremity stage III sarcomas was identi® ed and
analyzed in a similar fashion.
9This group (357 cases
of stage III extremitysarcomas from the same clinical
database) was used as the comparison group for
purposes of statistical analysis. Multivariate analysis
of prognostic factors was conducted using the Cox
proportional hazards model.
10 Disease-speci® c and
overall survival was calculated from the date of entry
into the database until death or last day of follow-up.
Survival analysis was performed using the actuarial
method of Kaplan and Meier and comparisons
between groups were made by log-rank analysis.
11
Results
Patient and tumor characteristics
Fifteen of 3969 patients diagnosed with sarcoma had
pathologically con® rmed ESOS (Fig. 1).The median
age of these patients was 61 years, and two-thirds of
them were male (Table 1).
All tumors were deep (below the investing fascia)
in location and histologically high-grade, and all but
one located in the lower extremity. Three tumors
were less than 5 cm in greatest dimension and 12
were greater than 5 cm.
Treatment and outcomes
All patients underwent an operation, one requiring
an amputation and 14 receivinglimb-sparingsurgery.
The microscopicmarginswere negative in 13 patients
and unknown (unable to be veri® ed from referring
institution)in the remainingtwo patients.In addition
to surgery, three patients received chemotherapy, two
Figure 1. Microscopic appearance of an ESOS showing neoplastic osteoid (large arrow) and focal cartilage matrix production (small
arrow) by malignant stromal cells;histologic features otherwise indistinguishable from primary osteogenic sarcoma of bone.
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three patients received a combination of both (Table
2).
The median follow-up for all patients was 35
monthsand for survivorswas 28 months(range3± 200
months). Six patients recurred at distant sites (all in
the lung) and one patient recurred both locally and
in the lung.Seven patients have died of their disease,
four are alive without evidence of disease, two are
alive with diseaseand two died of other causes.Three
of the four patients who are alive without disease
received no adjuvant therapy.
The disease-speci® c and overall 5-year survival for
patients with extraskeletal osteosarcomais 50%.Table
3 shows a comparisonbetween all patients with ESOS
and a similar group of stage III extremity sarcoma
patients selected to have large, deep and high-grade
sarcomas. For reference purposes, similar adverse
factors from a published report (using the same
database) of all extremity sarcomas are also shown in
the table. The difference in 5-year disease-speci® c
survival(50% versus38%) is notsigni® cantly different
by log-rank analysis (p=0.4). This ® nding is better
illustrated by the similar survival curves in Fig. 2.
The relatively small number of patients in the ESOS
group is re¯ ected by the fact that a single death at 61
months results in a drop in disease-speci® c survival
from 50% to 40%. Overall survival is likewise not
signi® cantly different between groups (curves not
shown, p=0.35).
Discussion
To our knowledge,this is the only analysis of patients
with ESOS reported in the English literature that has
been followed prospectively.Strict pathologic criteria
were adhered to in categorizingthe sarcomaas ESOS,
ensuring that the presence of malignant osteoid
formation was more than a focal process and that the
tumor lacked connection with bone. Although there
were larger series reported in the literature, these
studies may suffer from their retrospective nature
with a long look-back period and poor control over
historical pathologic and clinical information.
2,5,12
ESOS is an unusual malignant mesenchymal
neoplasm, representingapproximately 1% of all soft-
tissue sarcomas.
13,14 In our large database spanning
17 years at the Memorial Sloan± Kettering Cancer
Center, ESOS represents 0.04% of all sarcomas
prospectively analyzed. The male to female ratio of
2:1 observed in this study is similar to that reported
in some series;however,others have found no gender
difference.
2,4,5,12 The median age of 61 years is
considerably older than is generally reported in other
retrospective series evaluating ESOSs and for all
extremity sarcomas as a group.
1,3,7 The majority of
these sarcomas were deep, large and high-grade in
nature. Most reports also noted the predilection for
these tumors to be deep-seated and large (mean size
8± 10 cm) at the time of diagnosis. Plain radiographs
occasionally revealed extraskeletal ossi® cation, but
are not a reliable means for detection or diagnosis.
CT and MRI may be helpful but are not speci® c for
diagnosing these tumors.
The current series found only one tumor in the
upper extremity, none in the retroperitoneum and
the remainder in the lower extremity. Most other
series also demonstrated predominance of the lower
extremity location, with the thigh being the most
common subsite.
2,4
ESOSs were generally treated according to the
standard algorithm used for extremity sarcomas at
the Memorial Sloan± Kettering Cancer Center.Limb-
sparing surgery is used whenever possible, with the
decisionfor adjuvant radiation or chemotherapymade
on an individual basis depending on risk factors. In
Table 1. Summary of patient and tumor characteristics
ESOS characteristic (N=15)
Age (years)
Median 61
Range 40± 83
Sex
Male 10
Female 5
Site
Lower extremity 14
Upper extremity 1
Size
<5 cm 3
5± 10 cm 5
>10 cm 7
Grade
High 15
Microscopic margin
Positive 0
Negative 13
Unknown 2
Table 2. Treatment and outcomes
Option N
Surgery
Limb-sparing 14
Amputation 1
Other therapy
Chemotherapy 3
Radiation 2
Both 3
Recurrence
Local and distant 1
Distant 6
Status
Died of disease 7
Died of other disease 2
Alive with disease 2
No evidence of disease 4
Median survival (months) 26
Follow-up time (months)
Mean 53
Median (all) 35
Median (survivors) 28
Range 3± 200
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therapy are offered to patients with incomplete
resections and to those with large (>5 cm) or high-
grade lesions.There was only one local recurrence,
and this patient recurred with both local and distant
metastasis.As with other extremity sarcomas,distant
metastasis was the most frequent cause of death.
7
Though the total numbers are small, the type of
adjuvant therapy treatment employed did not appear
to in¯ uence survival.
The overall poor survival reported in previous
retrospectivestudiesimpliedthat ESOSscarrya worse
prognosis than other sarcomas.
2,3,5,15 A recent study
of all extremity sarcomas treated at the Memorial
Sloan± Kettering Cancer Center reported an overall
5-year survival rate of 76% which is considerably
better than the 50% 5-year survival rate for patients
with ESOS.
7 In that study, patients with ESOS were
combined with patients who had uncommon
histologic subtypes. The group with uncommon
histologic subtypes comprised 12% of all extremity
sarcoma patients and had a 5-year disease-speci® c
survival of 65%.A still more accurate comparisonfor
this ESOS group would be with a comparable group
of patients with deep, large and high-grade sarcomas
of the extremity. As seen in the survival curves from
Figs 2 and 3, there is no signi® cant difference in
overall or disease-speci® c survival when ESOSs are
compared with a comparable group of stage III
extremity sarcomas.
In conclusion, ESOS represents an unusual soft-
tissue sarcoma that occurs as a large, deep and high-
grade lesion of the extremities in older patients.The
clinical and pathologic differential diagnosis includes
myositis ossi® cans and malignant ® brous histiocy-
toma with focal bone metaplasia. Extraskeletal osteo-
genic sarcomas are grossly con® ned within the soft
tissue, without attachment to the underlying bony
structures.The pathologic diagnosis is con® rmed by
the presence of neoplastic osteoid, with or without
cartilage matrix, produced by the malignant mesen-
chymal cells, identical morphologically to primary
osteogenic sarcoma of the bone. Clinically, the
prognosis for ESOS is similar to that for other
Table 3. Comparison of ESOS with other extremity soft-tissue sarcomas
ESOS
Extremity
stage III
Extremity
all
7
Number 15 357 1041
Age (years)
Median 61 54 51
Range 40± 83 16± 75 16± 89
Gender (%)
Male 67 60 53
Female 33 40 47
Size (%)
<5 cm 20 Ð 41
5± 10 cm 33 Ð 28
>10 cm 47 100 25
Grade (%)
Low Ð Ð 65
High 100 100 35
Depth (%)
Super® cial Ð Ð 24
Deep 100 100 76
Site (%)
Upper 7 13 31
Lower 93 87 69
Margin (%)
Unknown 13 15 2
Positive Ð 24 23
Negative 87 61 75
Recurrence (%)
Local 7 12 17
Distant 47 42 22
Surgical treatment (%)
Amputation 7 11 10
Limb-sparing 93 75 87
Adjuvant treatment (%)
Chemotherapy 40 49 23
Radiation therapy 33 56 40
Median follow-up (months) 35 31 48
5-year survival (%)
Overall* 50 33 76
Disease-speci® c² 50 38 81
(* p=0.35, ² p=0.4)
122 M.D. McCarter et al.comparably staged extremity sarcomas. Treatment
decisions regarding adjuvant chemotherapy or radia-
tion therapy for ESOS shouldbe individualized,based
on the assessmentof relative risk factors.Suchtumors
need not be excluded from clinical trials, including
soft-tissue sarcomas based on histology alone.
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Figure 2. Disease-speci® c survival for ESOS and stage III extremity sarcoma.
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